The Warwick Experience of the Oncotype DX® Breast Recurrence Score® Assay as a Predictor of Chemotherapy Administration

Khan, M. A.; Henderson, Laura E.; Clarke, Dayalan; Harries, Simon; Jones, Lucie

doi:10.1159/000489131

Cited by 8 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study from Australia that included 235 patients with LN– BC, ACT was recommended to 89 patients, but only to 37 of them when the results of ODX assay were considered indicating treatment de-escalation in 58% of patients [22]. A study from the UK reported that 43% patients were spared chemotherapy when the results of the ODX assay were considered [23].…”

Section: Discussionmentioning

confidence: 99%

“…More recently, the value of ODX assay was investigated prospectively in the TAILOR-X trial. Patients with midrange RS (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25) were randomly assigned to receive either chemo-endocrine therapy or endocrine therapy alone. Results showed that ACT did not improve the outcome of these patients [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria

et al. 2020

View full text Add to dashboard Cite

Introduction: Oncotype DX assay recurrence score (ODX-RS) cutoff values have recently changed after the publication of the TAILOR-X trial results. We aim to explore decisions for adjuvant chemotherapy (ACT) based on physicians' clinical assessment and the evolving ODX-RS. Methodology: Patients who underwent ODX testing after curative surgical resection of estrogen receptor positive (ER+), Her2 non-overexpressed (Her2-) and lymph node-negative (LN-) breast cancer (BC) were eligible. Management of these patients was guided by the results of the old ODX-RS-1 (< 18, 18-30, and ≥31) risk grouping. For the purpose of this study, treatment decisions were also assumed according to TAILOR-X results (ODX-RS-2). Decisions of 3 medical oncologists on ACT were solicited by blinding them to the RS to investigate concordance with ODXA RS-1 and 2 recommendations. Results: Sixty-six consecutive patients were included. Median age was 50.5 (range: 21-73) years. There was 1 male patient, and 37/65 females (56.9%) were premenopausal. Among the 3 oncologists, recommendations for ACT based on clinical assessment were discrepant in 29 (43.9%) patients. Based on majority consensus (≥2 oncologists), ACT would have been recommended to 22/41 (53.7%) and 22/46 (47.82%) patients with low-risk tumors according to ODX-RS-1 and ODX-RS-2, respectively. Compared to ODX-RS-1, ODX-RS-2 identifies 12% (46 vs. 41) more low-risk patients and 66% (20 vs. 12 patients) more high-risk patients. Conclusion: Overtreatment and discrepancies in the management of patients with ER+/ Her2-/LN-early BC can be minimized by the implementation of ODX genomic assay. Some differences in ACT recommendations exist between ODX-RS-1 and ODX-RS-2.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Oncotype DX is a widely-used prognostic assay for the ERpositive breast cancers [85,86]. This assay utilizes the expression patterns of 16 cancer-associated genes and 5 house-keeping genes to evaluate the possibilities of a breast cancer to grow and to respond to the chemotherapeutic treatments.…”

Section: F Comparison With the Existing Gene Panels For Breast Cancersmentioning

confidence: 99%

Survival Time Prediction of Breast Cancer Patients Using Feature Selection Algorithm Crystall

Liu

Zheng

et al. 2021

IEEE Access

View full text Add to dashboard Cite

Breast cancer is one of main causes of death for women. Most of the existing survival analyses focus on the features' associations with whether the patients may survive five years or not. The personalized question remains largely unresolved about how long a breast cancer patient will live. This study aims to predict the patient-specific survival time of breast cancer patients. It formulates the personalized question into two machine learning problems. The first problem is the binary classification of whether a patient will live longer than five years or not. The second one is to build a regression model to predict the patient's survival time within five years. The methylome of a breast cancer patient is used for the prediction. A new algorithm Crystall is presented to find the methylomic features for this regression model. Our models perform well in the above two problems, and achieve the mean absolute error (MAE) of about 1 month for predicting how long a breast cancer patient will live within five years. The detected biomarker genes demonstrate close connections with breast cancers.

show abstract

“…It accounts for 15% of all newly diagnosed cancers and also is considered to be the most common female cancer. Up to 80% of these cases are categorized as early breast cancer [1,2].…”

Section: Introductionmentioning

confidence: 99%

The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer

Al‐Zawi

2021

Medical Research Journal

View full text Add to dashboard Cite

Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-positive, human epidermal growth factor receptor-2 negative, lymph-node negative early breast cancer in high-or low-recurrence risk groups. It has a guiding significance for whether post-operative chemotherapy or only hormonal manipulation is selected as an adjuvant treatment.Aims: Assess the impact of the Oncotype DX recurrence score on adjuvant chemotherapy-related management decision-making in the cases of ER+ve, HER2-ve, LN-ve early breast cancer in our local unit.Material and methods: A cohort of 76 patients with early breast cancer were included, two had bilateral disease. All were operated for estrogen-receptor-positive, human epidermal growth factor receptor-2 negative, lymph-node negative early breast cancer. Tumor grade, Ki67 proliferative index, PREDICT and Oncotype DX recurrence score results were obtained in addition to the offered treatment information for each case.Results: After the primary tumor surgery and an Oncotype DX recurrence score assessment, 18 patients (24%) were eligible for adjuvant chemotherapy; out of them, 10 patients (56%) had a chemotherapy absolute survival benefit of > 15% at 10 years, where 5 patients (30%) had a chemotherapy relative survival benefit of ~ 6.5%, 3 patients (17%) had a chemotherapy relative survival benefit of ~1.6%. In this cohort, 10 patients (13%) had a low Oncotype DX recurrence score; however, they received adjuvant chemotherapy based on other clinico-biological parameters. The other 48 patients (63%) with a low recurrence risk were spared potential adverse events related to the systemic therapy. Based on the menopausal status, every patient had received suitable hormonal manipulation therapy. The data also revealed the absence of a relationship between the Ki67 proliferative index and the Oncotype DX recurrence score (p = 0.06); moreover, the size of the tumor did not correlate with the Oncotype DX recurrence score (p = 0.5). Conclusion:The Oncotype DX recurrence score provides a credible prediction of distant disease recurrence risk in early breast cancer; however, it does not correlate with other prognostic markers, such as the Ki67 proliferative index as well as the tumor size. In this cohort, the use of the Oncotype DX recurrence score led to a 24% rate of treatment recommendations in the direction of adjuvant chemotherapy in addition to anti-hormonal therapy for estrogen-receptor-positive, human epidermal growth factor receptor-2 negative, lymph-node negative early breast cancer.

show abstract

The Warwick Experience of the Oncotype DX® Breast Recurrence Score® Assay as a Predictor of Chemotherapy Administration

Cited by 8 publications

References 16 publications

Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria

Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria

Survival Time Prediction of Breast Cancer Patients Using Feature Selection Algorithm Crystall

The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer

Contact Info

Product

Resources

About